Evidence map›Paper›PMID 41366613›Full record

Trial reportHigh blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension2026

Dapagliflozin Reduces Ambulatory Arterial Stiffness Index in CKD Patients with and Without Diabetes Independently of Blood Pressure Control: Results from the GLUcose Transport and Renal PROtection in Chronic Kidney Disease (GLUTREPRO) Trial.

Elisa Russo, Francesca Cappadona, Lucia Macciò, Julie Di Vincenzo, Michela Piaggio, Daniela Verzola, Giuseppe Chirco, Giacomo Garibotto, Pasquale Esposito, Francesca Viazzi

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT05998837. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05998837 phase2 / phase3completed

Single-center, Randomized, Controlled Study to Evaluate the Effects of a Six-month Treatment With Renal Glucose Transport Inhibitor (SGLT2i) Drugs on Markers of Senescence, Inflammation and Tubulointerstitial Damage in the Kidney of Patients With Chronic Kidney Disease With or Without Type 2 Diabetes

Ran2021Enrolled34Registered outcomes8Posted comparisons0ConditionsChronic Kidney Disease, Diabetes Mellitus, Type 2, HypertensionArmsDapagliflozin 10mg Tab, Placebo
Open the trial in the graph
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elisa RussoDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Francesca CappadonaNephrology, dialysis and transplantation Unit, IRCCS Policlinico San Martino, Genova, Italy.
Lucia MacciòDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Julie Di VincenzoDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Michela PiaggioDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Daniela VerzolaDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Giuseppe ChircoNephrology, dialysis and transplantation Unit, IRCCS Policlinico San Martino, Genova, Italy.
Giacomo GaribottoDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Pasquale EspositoDepartment of Internal Medicine, University of Genoa, Genoa, Italy.
Francesca ViazziDepartment of Internal Medicine, University of Genoa, Genoa, Italy. francesca.viazzi@unige.it.ORCID http://orcid.org/0000-0003-4219-7043

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSodium-glucose cotransporter 2 inhibitors (SGLT2i) confer cardiovascular and renal protection, but their impact on blood pressure (BP) and vascular stiffness in chronic kidney disease (CKD) is not fully defined.

aimTo investigate the effect of dapagliflozin on 24h-BP behavior and ambulatory arterial stiffness index (AASI) as a predefined secondary outcome of the GLUTREPRO trial.

methodsIn this randomized trial, 32 patients with albuminuric CKD received dapagliflozin 10 mg/day or placebo on top of optimized standard therapy. Laboratory tests, ambulatory blood pressure monitoring (ABPM), and bioimpedance were performed at baseline and during follow-up. The study comprised a 6-month randomized phase and a 12-month open-label phase, analyzed with mixed-effects models.

resultsBaseline characteristics were balanced (mean age 58 ± 14 years, 37% diabetes, eGFR 50.6 ± 17.3 ml/min/1.73 m

conclusionIn patients with albuminuric CKD, dapagliflozin lowered AASI independently of BP control and sodium handling, suggesting favorable vascular remodeling in both diabetic and non-diabetic patients.

trial registrationThe study was registered in the EU Clinical Trials Register (EudraCT: 2020-004835-26) and online at the https://www. CLINICALTRIALS: gov (Unique identifier: NCT05998837, 13th April 2021).

Indexed as

AlbuminuriaBenzhydryl CompoundsBlood GlucoseBlood PressureGlucosidesHypertensionKidneyRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsVascular StiffnessAgedBiomarkersBlood Pressure Monitoring, AmbulatoryFemaleGlomerular Filtration RateHumansBenzhydryl CompoundsBiomarkersBlood GlucosedapagliflozinGlucosidesSodium-Glucose Transporter 2 InhibitorsAmbulatory blood pressure monitoringBlood pressureChronic kidney diseaseSGLT2 inhibitionVascular stiffness

Identifiers

PMID41366613
PMCPMC12883519

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.